Philip Sloan

ORCID: 0000-0002-0142-0213
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Head and Neck Cancer Studies
  • Oral Health Pathology and Treatment
  • Oral and Maxillofacial Pathology
  • Salivary Gland Tumors Diagnosis and Treatment
  • Cancer Diagnosis and Treatment
  • Oral and gingival health research
  • Temporomandibular Joint Disorders
  • Head and Neck Surgical Oncology
  • Lung Cancer Treatments and Mutations
  • Radiomics and Machine Learning in Medical Imaging
  • Cancer, Hypoxia, and Metabolism
  • Periodontal Regeneration and Treatments
  • dental development and anomalies
  • Tumors and Oncological Cases
  • Bone Tumor Diagnosis and Treatments
  • Ear and Head Tumors
  • RNA modifications and cancer
  • Bone and Dental Protein Studies
  • Laser Applications in Dentistry and Medicine
  • Dental Implant Techniques and Outcomes
  • Oral health in cancer treatment
  • Connective tissue disorders research
  • Cancer-related Molecular Pathways
  • Bone health and treatments
  • Cancer-related gene regulation

Newcastle upon Tyne Hospitals NHS Foundation Trust
2015-2025

Newcastle University
2015-2025

Newcastle upon Tyne Hospital
1984-2024

University Dental Hospital of Manchester
1997-2023

Royal Victoria Infirmary
2010-2023

Engineering and Physical Sciences Research Council
2016-2020

Queen Elizabeth II Health Sciences Centre
2018

Emory University
2018

Dalhousie University
2018

Cleveland Clinic
2018

Abstract Affymetrix U133plus2 GeneChips were used to profile 59 head and neck squamous cell cancers. A hypoxia metagene was obtained by analysis of genes whose in vivo expression clustered with the 10 well-known hypoxia-regulated (e.g., CA9, GLUT1, VEGF). To minimize random aggregation, strongly correlated up-regulated appearing >50% clusters defined a signature comprising 99 genes, which 27% previously known be associated. The median RNA an independent prognostic factor for...

10.1158/0008-5472.can-06-3322 article EN Cancer Research 2007-04-01

Abstract Purpose: Human papillomavirus-16 (HPV16) is the causative agent in a biologically distinct subset of oropharyngeal squamous cell carcinoma (OPSCC) with highly favorable prognosis. In clinical trials, HPV16 status an essential inclusion or stratification parameter, highlighting importance accurate testing. Experimental Design: Fixed and fresh-frozen tissue from 108 OPSCC cases were subject to eight possible assay/assay combinations: p16 immunohistochemistry (p16 IHC); situ...

10.1158/1078-0432.ccr-11-0388 article EN Clinical Cancer Research 2011-10-01

Inhibition of monocarboxylate transporter (MCT) 1-mediated lactate transport may have cytostatic and/or cytotoxic effects on tumor cells. We report results from the dose-escalation part a first-in-human trial AZD3965, first-in-class MCT1 inhibitor, in advanced cancer.

10.1158/1078-0432.ccr-22-2263 article EN Clinical Cancer Research 2023-01-18

Human papillomavirus (HPV) testing in oropharyngeal squamous cell carcinoma (OPSCC) is now advocated. Demonstration of transcriptionally active high-risk HPV (HR-HPV) fresh tumour tissue considered to be the analytical 'gold standard'. Clinical has focused on formalin-fixed paraffin-embedded (FFPE) at expense sensitivity and specificity. Recently, a novel RNA situ hybridisation test (RNAscope) been developed for detection HR-HPV FFPE tissue; however, validation against standard' not...

10.1038/bjc.2013.63 article EN cc-by-nc-sa British Journal of Cancer 2013-02-14

Oncogenic human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (SCC) is a subtype of head-and-neck cancer with distinct clinical and prognostic profile. While there are calls to undertake HPV testing for SCCs within the diagnostic setting trials, currently no internationally accepted standards.142 tonsil were tested using p16 immunohistochemistry (IHC), high-risk DNA in situ hybridisation (ISH) polymerase chain reaction (PCR; GP5+/6+ primers).There high levels...

10.1136/jcp.2010.088450 article EN Journal of Clinical Pathology 2011-02-23

Abstract This is the official guideline endorsed by specialty associations involved in care of head and neck cancer patients UK. There has been significant debate management oropharyngeal last decade, especially light increased incidence, clarity on role human papilloma virus this disease treatment responsiveness positive cancers. paper discusses evidence base pertaining to provides recommendations for group receiving care. Recommendations • Cross-sectional imaging required all cases...

10.1017/s0022215116000505 article EN cc-by The Journal of Laryngology & Otology 2016-05-01

Pericytes isolated from the bovine retinal microvasculature retain characteristic features of their in vivo counterparts, such as presence glycogen deposits, long filamentous processes, prominent microfilament bundles and ability to display two distinct reversible phenotypes. Time-lapse video-microscopy demonstrated that pericytes tend overlap aggregate, even sparse cultures. After reaching confluence, they form multilayered areas retract away each other, resulting formation multicellular...

10.1242/jcs.97.3.449 article EN Journal of Cell Science 1990-11-01

10.1054/ijom.2002.0292 article EN International Journal of Oral and Maxillofacial Surgery 2002-11-12

Involvement of the cervical lymph nodes is most important prognostic factor for patients with oral/oropharyngeal squamous cell carcinoma (OSCC), and decision whether to electively treat clinically negative necks remains a controversial topic. Sentinel node biopsy (SNB) provides minimally invasive method determining disease status basin, without need formal neck dissection. This technique potentially improves accuracy histologic nodal staging avoids overtreating three-quarters this patient...

10.1245/s10434-009-0726-8 article EN cc-by-nc Annals of Surgical Oncology 2009-09-30

10.1016/0266-4356(90)90136-9 article EN British Journal of Oral and Maxillofacial Surgery 1990-04-01

10.1016/s0901-5027(05)80196-1 article EN International Journal of Oral and Maxillofacial Surgery 1990-04-01
Coming Soon ...